Synthesis and primary cytotoxic screening of some 3-sulfonamide substituted benzamido-benzimidazolones

Iranian Journal of Pharmaceutical Research

Volumn 4, Issue 1, 2005, Pages 43-56

  Khodarahmi, Ghadam Ali ^a   Chen, Pei Yu ^b,c   Hakimelahi, Gholam Hosein ^a,d   Chern, Ji Wang ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Maine Medical Center Research Institute   (United States)

^d ACADEMIA SINICA   (Taiwan)

Author keywords

Benzimidazolone; CDK2; Cytotoxicity; Design; Sulfonamide

Indexed keywords

EID: 84859546148     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: 10.22037/IJPR.2010.616     Document Type: Article

References (18)

1. Sielecki TM, Boylan JF, Benfield PA and Trainor GL. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation J. Med. Chem. (2000) 43: 1-18
2. Davis TG, Pratt DJ, Endicott JA, Johnson NL and Noble MEM. Structure-based design of cyclin-dependent kinase inhibitors Pharmacology and Therapeutics (2002) 93: 125-133
3. Fischer PM and Lane DP. Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics Curr. Med. Chem. (2000) 7: 1213-1245
4. Misra RN, Rawlins DB, Xiao HY, Shan W, Bursurker I, Kellar KA, Mulheron JG, Sack JS, Tokarski JS, Kimball SD and Webster KR. 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases Bioorg. Med. Chem. Lett. (2003) 13: 1133-1136
5. Fabbro DF, Ruetz S, Buchdunger E, Cowan-Jacob, SW, Fendrich G, Liebetanz J, Mestan J, O’Reilly T, Peter P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P and Manley P W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs Pharmacology and Therapeutics (2002) 93: 79-98
6. Bramson HN, Corona J, Davis ST, Dickerson SH, Edelstein M, Frye SV, Gampe RT Jr, Harris PA, Hassell A, Holmes WD, Hunter RN, Lackey KE, Lovejoy B, Luzzio MJ, Montana V, Rocque WJ, Rusnak D, Shewchuk L, Veal JM, Walker DH and Kuyper LF. Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis J. Med. Chem. (2001) 44: 4339-58
7. Luk KC, Simcox ME, Schutt A, Rowan K, Thompson T, Chen Y, Kammlott U, DePinto W, Dunten P and Dermatakis A. A new series of potent oxindole inhibitors of CDK2 Bioorganic & Medicinal Chemistry Letters (2004) 14: 913–917
8. Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH and Kuyper LF. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK InhibitorsPrevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors Science (2001) 291: 134-137
9. Turber TC, Prince A and Halpern O. An Alternative Synthesis of Tiopinac J. Heterocyclic Chem. (1982) 19: 961-965
10. Kruse LI, Kaiser C, DeWolf, WE, Frazee JS, Ross ST, Wawro J, Wise M, Flaim KE, Sawyer JL, Erickson RW, Ezekie1 M, Ohlstein EH, and Berkowitz BA. Multisubstrate Inhibitors of Dopamine a-Hydroxylase. Structure-Activity Relationships at the Phenethylamine Binding Site J. Med. Chem. (1987) 30: 486-494
11. Harrold MW, Wallace RA., Farooqui T, Wallace LJ, Uretsky N and Miller DD. Synthesis and D2 dopaminergic activity of pyrrolidinium, tetrahydrothiophenium, and tetrahydrothiophene analogs of sulpiride J. Med. Chem. (1989) 32: 874-880
12. Peet NP and Sunder S. Factors Which Influence the Formation of Oxadiazoles from Anthranilhydrazides and Other Benzoylhydrazines J. Heterocyclic Chem. (1984) 21: 1807-1816
13. Israili ZH, Perel JM, Cunningham RF, Dayton PG, Yu TF, Gutman AB, Long KR, Long RC and Goldstein J. Metabolites of probenecid. Chemical, physical, and pharmacological studies J. Med. Chem. (1972) 15: 709-713
14. Hayman DF, Petrow V, Stephenson O and Thomas AJ. Hypoglycaemic agents. II J. Pharm. Pharmacol. (1962) 14: 451-455
15. English J. P, Clark J. H, Shepherd R. G, Marson H. W, Krapcho J, and Roblin R. O. Studies in Chemotherapy. XIV. Antimalarials. The Synthesis of Substituted Metanilamides and Related Compounds J. Am. Chem. Soc. (1946) 68: 1039-1049
16. Meth-Cohn O and Smith DI. N-bridged heterocycles. Part 5. αω-Bis-(2-oxobenzimidazolinyl)alkanes and-ethers as selective ligands for group-1 and-2 metals J. Chem. Soc. Perkin Trans. 1 (1982) 261-266
17. Davoll J and Laney DH. Some N-substituted 2-oxobenzimidazolines J. Chem. Soc. (1960) 308-314
18. Achour R, Essassi EM and Zniber R. Nouvelle synthese de l' (α-methyl vinyl)-9 methyl-3s-triazolo[4,3-a] benzimidazole a partir de la methyl-4benzodiazepine-1,5 one-2. Tetrehedron Letter (1988) 29: 195-198